Medical Research Labarotory, DoH, Aarhus University Hospital
Aarhus, 8200, Denmark
NCT Number: NCT04037722
This study evaluates the cardiovascular effects of adding the ketone body 3-hydroxy butyrate (3-OHB) to whey protein during human endotoxemia. Further, this study compares cardiovascular changes during healthy and catabolic conditions.
Participants will receive isocaloric, isonitrogenous beverages of either whey or 3-OHB+whey in a randomized crossover design during either healthy (overnight fast) or catabolic conditions (inflammation/endotoxemia + 36 h fast and bed rest).
Looking for future studies?
Notify Me20 year–40 year
Male
Interventional
Not applicable
Aarhus, 8200, Denmark
Background: A newly published study found beneficial cardiovascular effects of 3-OHB infusion in a population with chronic heart failure, significantly increasing cardiac output. Similar effects on cardiac output were observed in healthy volunteers. These findings pave the way for 3-OHB as a therapeutic nutritional supplement, since it is well-absorbed during oral consumption. However, it is unknown whether the cardiovascular effects of 3-OHB persist during a sepsis-like catabolic state and when administered orally.
Aim: This study aims to investigate the cardiovascular effects of adding the ketone body 3-hydroxy butyrate (3-OHB) to whey protein during a human disease model, comprising endotoxemia + bed rest + fast.
Hypothesis:
Interventions:
In a randomized crossover design, eight healthy, lean, young men will undergo either:
i) Healthy conditions (overnight fast) + whey protein^
ii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest*) + whey protein^
iii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest*) + 3-OHB/whey protein^"
*LPS will be administered (1 ng/kg) the day prior to the study together with fast and bed rest. On the study day LPS (0.5 ng/kg) will be injected.
^Beverages will be isonitrogenous and isocaloric (fat will be added) with 45 g whey protein + 20 g maltodextrin. Bolus/sip administration will be applied (1/3 bolus, 1/2 sip)
" 50 grams of 3-OHB will be orally administered (1/2 bolus, 1/2 sip)
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
•>10 hours of exercise/weak
45 g whey + 20 g maltodextrin
50 g ketone + 45 g whey + 20 g maltodextrin
Time frame: Measured during the basal period and after 1.5 hours of intervention
Echocardiographic changes in left ventricular outflow tract velocity time integral from the basal period and after 1.5 hours of intervention
Time frame: Measured during the basal period and after 1.5 hours of intervention
Echocardiographic changes in LVEF from the basal period and after 1.5 hours of intervention
Time frame: Measured during the basal period and after 1.5 hours of intervention
Echocardiographic changes in GLS from the basal period and after 1.5 hours of intervention
Time frame: Measured during the basal period and after 1.5 hours of intervention
Echocardiographic changes in S´ Max from the basal period and after 1.5 hours of intervention
Time frame: Measured during the basal period and after 1.5 hours of intervention
Changes in blood pressure from the basal period and after 1.5 hours of intervention
Time frame: Measured during the basal period and after 1.5 hours of intervention
Changes in heart rate from the basal period and after 1.5 hours of intervention
Time frame: Measured during the basal period and after 1.5 hours of intervention
Changes in axillary temperature from the basal period and after 1.5 hours of intervention
Time frame: Measured after 2 hours of basal period
Echocardiographic difference in LVEF during the basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)
Time frame: Measured after 2 hours of basal period
Echocardiographic difference in GLS during the basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)
Time frame: Measured after 2 hours of basal period
Echocardiographic difference in S´ Max during the basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)
Time frame: Measured after 2 hours of basal period
Difference in axillary temperature after 2 hours basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)
Time frame: Measured after 2 hours of basal period
Difference in heart rate after 2 hours basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)
Time frame: Measured after 2 hours of basal period
Difference in blood pressure after 2 hours basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)
University of Aarhus
Other
Echocardiographic Changes After Oral Intake of 3-hydroxy Butyrate+Whey in a Human Endotoxemia Model
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05269537
Anesthesia, Spinal, Cardiac Output
Al Mansurah, Dakahlia Governorate, Egypt
View Trial DetailsNCT03172689
Cardiac Output
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT04941248
Cardiac Output
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT05648279
Anesthesia, Cardiac Output
Graz, Austria
View Trial Details